Chronic GvHD After RIC MRD HCT for AML with Post-Transplant Cyclophosphamide GvHD Prophylaxis

home / case-based-peer-perspectives / chronic-gvhd-after-ric-mrd-hct-for-aml-with-post-transplant-cyclophosphamide-gvhd-prophylaxis

Yi-Bin Chen, MD, presents an overview of graft versus host disease (GVHD), covering a patient case, first-line and second-line treatment options, associated toxicities, and the potential impact of ongoing clinical trials on the future of GVHD treatment.